ARS Pharmaceuticals, Inc. (SPRY) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $9.80 (-0.41%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Roanna Ruiz | Leerink Partners | $26.00 | +165.3% |
| Nov 4, 2025 | Kyle Bauser | Roth Capital | $30.00 | +206.1% |
| Aug 19, 2024 | Josh Schimmer | Cantor Fitzgerald | $30.00 | +206.1% |
| Aug 12, 2024 | Strong Buy | Raymond James | $22.00 | +124.5% |
| Jul 25, 2024 | Ryan Deschner | Raymond James | $18.00 | +83.7% |
| Mar 5, 2024 | Roanna Ruiz | Leerink Partners | $18.00 | +83.7% |
Top Analysts Covering SPRY
SPRY vs Sector & Market
| Metric | SPRY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +163.4% | +11474.8% | +17.1% |
| P/E Ratio | -4.57 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $35M | $36M | $38M | 6 |
| 2026-09-30 | $54M | $56M | $59M | 4 |
| 2026-12-31 | $38M | $40M | $42M | 5 |
| 2027-03-31 | $46M | $47M | $50M | 3 |
| 2027-06-30 | $74M | $76M | $80M | 3 |
| 2027-09-30 | $115M | $120M | $125M | 3 |
| 2027-12-31 | $81M | $84M | $88M | 3 |
| 2028-12-31 | $428M | $428M | $428M | 6 |
| 2029-12-31 | $443M | $583M | $657M | 5 |
| 2030-12-31 | $525M | $690M | $778M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.47 | $-0.39 | $-0.27 | 4 |
| 2026-09-30 | $-0.27 | $-0.26 | $-0.25 | 1 |
| 2026-12-31 | $-0.40 | $-0.37 | $-0.36 | 2 |
| 2027-03-31 | $-0.45 | $-0.42 | $-0.40 | 2 |
| 2027-06-30 | $-0.21 | $-0.20 | $-0.19 | 1 |
| 2027-09-30 | $0.20 | $0.20 | $0.22 | 1 |
| 2027-12-31 | $-0.08 | $-0.07 | $-0.07 | 2 |
| 2028-12-31 | $-0.92 | $0.22 | $0.82 | 6 |
| 2029-12-31 | $0.77 | $1.11 | $1.30 | 4 |
| 2030-12-31 | $1.20 | $1.75 | $2.03 | 2 |
Frequently Asked Questions
What is the analyst consensus for SPRY?
The consensus among 1 analysts covering ARS Pharmaceuticals, Inc. (SPRY) is Buy with an average price target of $25.50.
What is the highest price target for SPRY?
The highest price target for SPRY is $30.00, set by Kyle Bauser at Roth Capital on 2025-11-04.
What is the lowest price target for SPRY?
The lowest price target for SPRY is $18.00, set by Roanna Ruiz at Leerink Partners on 2024-03-05.
How many analysts cover SPRY?
1 analysts have issued ratings for ARS Pharmaceuticals, Inc. in the past 12 months.
Is SPRY a buy or sell right now?
Based on 1 analyst ratings, SPRY has a consensus rating of Buy (2.00/5) with a +163.4% upside to the consensus target of $25.50.
What are the earnings estimates for SPRY?
Analysts estimate SPRY will report EPS of $-0.39 for the period ending 2026-06-30, with revenue estimated at $36M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.